Document is current
Any future updates will be listed below
-
Authors
Wei, Jin https://orcid.org/0000-0002-2832-1610
Patil, Ajinkya https://orcid.org/0000-0003-1080-1146
Collings, Clayton K.
Alfajaro, Mia Madel
Liang, Yu
Cai, Wesley L.
Strine, Madison S. https://orcid.org/0000-0001-8572-1314
Filler, Renata B.
DeWeirdt, Peter C. https://orcid.org/0000-0002-4707-7940
Hanna, Ruth E.
Menasche, Bridget L.
Ökten, Arya https://orcid.org/0000-0002-7460-7951
Peña-Hernández, Mario A.
Klein, Jon https://orcid.org/0000-0002-3552-7684
McNamara, Andrew
Rosales, Romel https://orcid.org/0000-0001-5326-4753
McGovern, Briana L.
Luis Rodriguez, M.
García-Sastre, Adolfo https://orcid.org/0000-0002-6551-1827
White, Kris M. https://orcid.org/0000-0003-0889-0506
Qin, Yiren
Doench, John G. https://orcid.org/0000-0002-3707-9889
Yan, Qin https://orcid.org/0000-0003-4077-453X
Iwasaki, Akiko https://orcid.org/0000-0002-7824-9856
Zwaka, Thomas P.
Qi, Jun https://orcid.org/0000-0002-1461-3356
Kadoch, Cigall https://orcid.org/0000-0002-4058-5985
Wilen, Craig B. https://orcid.org/0000-0003-2495-9403
-
Funding
Funding for this research was provided by:
Burroughs Wellcome Fund
G. Harold and Leila Y. Mathers Foundation
Richard and Susan Smith Family Foundation
Ludwig Family Foundation and Emergent Ventures Fast Grant
National Science Foundation
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (T32 HL 007974)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R21AI157835, 75N93021C00014, U19AI135972)
United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-19-2-319 0020)
U.S. Department of Defense (W81XWH-20-1-0270)
Huffington Foundation
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (1DP2CA195762-01)
- License Information
-
More Information
Article History
Received: 11 August 2022
Accepted: 23 January 2023
First Online: 9 March 2023
Competing interests
: C.K. is the scientific founder, scientific advisor to the board of directors, scientific advisory board member, shareholder and consultant for Foghorn Therapeutics. C.K. also serves on the scientific advisory boards of Nereid Therapeutics, Nested Therapeutics and Fibrogen, and is a consultant for Cell Signaling Technology and Google Ventures. J.W., A.P., C.K. and C.B.W. have a patent pending related to this work. C.B.W. is a consultant for Exscientia and Bain Capital Life Sciences and sits on the scientific advisory board for ExcepGen. The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-FOLD LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences; Contrafect; 7Hills Pharma; Avimex; Vaxalto; Pagoda; Accurius; Esperovax; Farmak; Applied Biological Laboratories; Pharmamar; Paratus; CureLab Oncology; CureLab Veterinary; Synairgen and Pfizer, outside of the reported work. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott and AstraZeneca. A.G.-S. is the inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the ISMMS, outside of the reported work. J.G.D. consults for Microsoft Research, Abata Therapeutics, Maze Therapeutics, BioNTech, Sangamo and Pfizer. J.G.D. consults for and has equity in Tango Therapeutics. J.G.D. serves as a paid scientific advisor to the Laboratory for Genomics Research, funded in part by GSK, and the Innovative Genomics Institute, funded in part by Apple Tree Partners. J.G.D. receives funding support from the Functional Genomics Consortium: Abbvie, Bristol Myers Squibb, Janssen, Merck and Vir Biotechnology. J.G.D.’s interests are reviewed and managed by the Broad Institute in accordance with its conflict of interest policies. T.P.Z. is an inventor on patents and patent applications on the use of iPS cells and viruses, owned by the Icahn School of Medicine at Mount Sinai, New York. T.P.Z. is a founder and shareholder of Paratus Sciences. The other authors declare no competing interests.
